Ningxia Teder Pharmaceutical Co., Ltd., a famous trademark in Ningxia, is a high-tech enterprise dedicated to the R&D, production and sales of APIs, premixes and feed additives in China

Founded in 2000, Ningxia Terui Pharmaceutical Co., Ltd. is a national high-tech enterprise, one of the 30 non-public enterprises in Ningxia Hui Autonomous Region, with a state-level enterprise technology center, nearly 3,500 employees, total assets of 5 billion, bank credit rating of AAA, and an asset-liability ratio of 52%. The company consists of three subsidiaries: Ningxia Taiyixin Biotechnology Co., Ltd., Ningxia Finit Engineering Equipment Co., Ltd., Ningxia Hope Field Bioagricultural Technology Co., Ltd., and two branches: Ningxia Tairui Pharmaceutical Co., Ltd. Clean Energy Heating Branch and Ningxia Terui Pharmaceutical Co., Ltd. Helan Branch. The company is committed to the research and development, production and sales of veterinary antibiotic APIs, premixes and feed additives, among which tylosin, a veterinary antibiotic API, is the company's main product. The company has successively passed the GMP certification of veterinary drugs of the Ministry of Agriculture of the People's Republic of China, the ISO9000-14001 environmental quality system certification, the US FDA certification and the EU COS certification; At the same time, it has successively passed the quality audit certification of key enterprises in Poland, Germany, Belgium and other countries and regions, and the overseas market has been further expanded, and the company's sales performance has reached a new level.

The company combines the advantages of science and technology, production capacity and resources, and takes "talent as the foundation, marketing as the leader, scientific research as the backing, and management as the main line" to improve reform, innovation and development, improve internal management and improve product quality; Meet customer needs and expand market share; Seize market opportunities, develop production scale, implement the management idea of "fine, fine and beautiful" within the company, effectively improve the company's management level, and strive to achieve rapid development of the enterprise.

After nearly 10 years of market tempering and efficient operation, the company's products have rapidly developed from the production of a single antibiotic API to the production of tylosin, tylosin, tylodine, tilmicosin, chlortetracycline and other products, with the production capacity of three dosage forms of APIs, premixes and granules, and dozens of varieties. In 2009, the company entered the top 10 veterinary API production enterprises in China. The company's product tylosin has the largest production capacity in the world, and has developed into one of the largest manufacturers of veterinary antibiotics in the world.

Over the years, the company has continuously improved its sales network and actively obtained the right to import and export. On the basis of the domestic market, we actively explore the international market, and have set up two marketing systems, namely the domestic marketing center and the international marketing center, and the sales network radiates more than 30 central cities in China and major international sales markets. More than 80% of the products are exported to more than 80 countries and regions such as Brazil, India and Germany. The export volume of the company's product tylosin ranks first among domestic counterparts. In 2012, the company achieved an output value of 990 million yuan, a sales revenue of 590 million yuan, and a profit and tax of nearly 200 million yuan. The company's output value and sales revenue have grown steadily

The company has international advanced pharmaceutical equipment and testing instruments, established a complete quality management system, since the beginning of the establishment of the factory has formulated the quality standard of "always higher than the same industry", so that the product quality has always been maintained at the leading level in the country, strict product quality, to ensure that the products are all excellent factory. "Go scientific and technological innovation, create a world famous brand" is the basic idea of enterprise development, the enterprise attaches great importance to scientific research, pay attention to the selection, training and reserve of technical personnel, adopt the method of "going out, please come in", and has hired hundreds of professional and technical personnel from all over the country to engage in technology and production work. After years of development and accumulation, the company currently has strong technical strength in the core production links such as strain breeding and preservation, biological fermentation, refining and quality control.

Excellent quality and perfect service have won the trust of many customers and the recognition of all walks of life for the company. The company has successively won the honorary titles of "China's Outstanding Private Technology Enterprise", "China's Third Batch of Innovative Pilot Enterprises", and "Ningxia Safe and Secure Consumer Brand Enterprise". The company has been recognized by the National Development and Reform Commission as a national enterprise technology center and a national and local joint laboratory. In the same year, the company was awarded the fifth batch of national key leading enterprises in agricultural industrialization jointly recognized by the Ministry of Agriculture, the National Development and Reform Commission, the China Securities Regulatory Commission and other departments, and the commendation and award of the outstanding team for the implementation of the "Eleventh Five-Year Plan" of the Ministry of Science and Technology. Scientific and technological innovation has added strong stamina to the company's product production and business development. In the future, the company will continue to increase investment in science and technology, and strive to independently develop more and better new products, so as to lay a solid foundation for the sustainable, healthy and orderly development of the company.

Since its establishment, the company attaches great importance to environmental protection work, has been adhering to the management idea of "source control, comprehensive treatment", invested a lot of manpower, material and financial resources, has invested 420 million yuan to devote itself to environmental protection work, and has successively built sewage stations, flue gas dust removal, desulfurization projects, deodorization facilities, noise control, hazardous waste management and other environmental protection equipment and facilities. The level of environmental protection hardware and processing capacity have reached the national standard. The environmental protection department has installed online monitoring equipment in the company, real-time online monitoring, and the company's flue gas and sewage treatment are discharged after reaching the standard. For a long time, the company has been innovating the concept of environmental management, clarifying environmental protection tasks, strengthening environmental governance, paying close attention to the implementation of energy conservation and emission reduction, developing circular economy, and striving to develop Tederic into a "resource-saving, environment-friendly, and recycling-oriented" large-scale pharmaceutical enterprise.

At the end of 2009, the company was listed as a company to be listed by the Financial Office of the Autonomous Region and the Ningxia Securities Regulatory Bureau, and entered the listing counseling period. In August 2010, the company successfully completed the shareholding system restructuring and the convening of the three sessions, and established a modern enterprise management system in an all-round way, and became more perfect and sound in terms of management structure and standardized operation. In the same year, the relevant intermediaries have entered the company to carry out due diligence, after nearly two years of work, the due diligence of intermediaries has been basically completed, the company's listing materials have been declared, and are currently waiting for the final approval of the China Securities Regulatory Commission.

In the future, the company will be dominated by differentiated competition and large-scale development, organically combine scientific and technological advantages, production capacity advantages and resource advantages, strive to achieve rapid development of the enterprise, truly build our company into a world-class API production base, and make greater contributions to the local economy of Ningxia and China's biopharmaceutical industry.